Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
Dokumenttyp:
Meeting Abstract
Autor(en):
Apolo, Andrea B.; Powles, Thomas; Burotto, Mauricio; Bourlon, Maria Teresa; Hsieh, James J.; Basso, Umberto; Shah, Amishi Yogesh; Suarez, Cristina; Porta, Camillo; Barrios, Carlos H.; Gurney, Howard; Kessler, Elizabeth R.; Retz, Margitta; George, Saby; Escudier, Bernard; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Motzer, Robert J.; Choueiri, Toni K.